Introduction to the Drug
The drug with the National Drug Code (NDC) 64764-0750 is associated with ENTYVIO (vedolizumab), a biologic medication used for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) in adults[1].
Market Context
Biopharma and Biotech Industry Growth
The biopharmaceutical market, which includes drugs like ENTYVIO, is experiencing significant growth. As of 2024, the biopharma market size was estimated to be over $400 billion, with a projected compound annual growth rate (CAGR) of 7.56% between 2024 and 2029. The biotechnology sector is also expanding rapidly, with a market size of nearly $500 billion in 2020 and an estimated CAGR of 9.4% between 2021 and 2027[3].
Clinical Indications and Usage
ENTYVIO is specifically indicated for the treatment of:
- Moderately to severely active ulcerative colitis (UC)
- Moderately to severely active Crohn's disease (CD)[1].
This targeted therapy is part of a broader trend towards precision medicine, which is expected to continue shaping the biopharma and biotech industries in 2025[3].
Pricing Trends
Current Pricing
While specific pricing data for NDC 64764-0750 is not readily available in the provided sources, biologic drugs like ENTYVIO are generally high-cost therapies. The prices of such drugs can vary based on factors such as dosage, administration route, and market dynamics.
Price Projections
For 2025, drug price inflation is projected to be around 3.81%, driven by high-cost therapies and expanding indications. This trend suggests that the price of ENTYVIO could increase in line with these projections[4].
Market Dynamics
Regulatory Landscape
The regulatory landscape is evolving to keep pace with innovation in the biopharma and biotech industries. This includes more flexible and adaptive clinical trial designs, which can impact the development and approval timelines of drugs like ENTYVIO. These changes are expected to continue in 2025, potentially influencing the market availability and pricing of such medications[3].
Competitive Market
The market for biologic treatments for UC and CD is competitive, with several other drugs available. However, ENTYVIO's specific mechanism of action and targeted therapy approach can differentiate it from competitors, potentially stabilizing or increasing its market share.
Patient and Healthcare System Impact
Patient-Centered Care
There is a growing focus on patient-centered care in clinical trials and drug development. This shift towards more personalized and efficient healthcare can increase demand for targeted therapies like ENTYVIO, as they often offer better outcomes and quality of life for patients with specific conditions[3].
Healthcare Costs
The high cost of biologic drugs like ENTYVIO can be a significant burden on healthcare systems. However, these drugs often provide significant clinical benefits, which can justify their costs in terms of improved patient outcomes and reduced long-term healthcare expenditures.
Technological and Innovative Trends
Accelerated Clinical Trial Designs
Innovative clinical trial designs are becoming more prevalent, aiming to reduce the time and cost associated with drug development. These designs can help in bringing drugs like ENTYVIO to the market more quickly, which could impact pricing and availability[3].
AI and ML Technologies
The use of artificial intelligence (AI) and machine learning (ML) in drug development is on the rise. These technologies can enhance the efficiency of clinical trials, improve patient outcomes, and potentially reduce the costs associated with developing and marketing biologic drugs.
Key Takeaways
- ENTYVIO (vedolizumab) is a biologic drug indicated for the treatment of moderately to severely active UC and CD.
- The biopharma and biotech markets are experiencing significant growth, driven by advancements in technology and evolving regulatory frameworks.
- Drug price inflation for 2025 is projected to be around 3.81%, which could affect the pricing of ENTYVIO.
- The focus on patient-centered care and innovative clinical trial designs is expected to continue in 2025, influencing the market dynamics for biologic drugs.
- AI and ML technologies are increasingly being used to enhance drug development efficiency and patient outcomes.
FAQs
Q: What is ENTYVIO used for?
A: ENTYVIO (vedolizumab) is used for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) in adults.
Q: What is the current market size of the biopharma industry?
A: As of 2024, the biopharma market size was estimated to be over $400 billion.
Q: What is the projected price inflation for drugs in 2025?
A: Drug price inflation for 2025 is projected to be around 3.81%.
Q: How are clinical trial designs evolving?
A: Clinical trial designs are shifting towards more innovative and adaptive approaches to promote efficiency and reduce the exposure of patients to ineffective therapies.
Q: What role do AI and ML play in drug development?
A: AI and ML technologies are being used to enhance the efficiency of clinical trials, improve patient outcomes, and potentially reduce the costs associated with drug development.
Sources
- DailyMed: ENTYVIO- vedolizumab injection, powder, lyophilized, for solution.
- DrugPatentWatch: Latest drug prices and trends for NDC 51672-1387.
- TFS CRO: 5 Predictions for the Biopharma and Biotech Industries in 2025.
- DrugPatentWatch: Latest drug prices and trends for NDC 00641-1398.
